David A. Siegel Kronos Bio, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 175,400 shares of KRON stock, worth $168,384. This represents 0.0% of its overall portfolio holdings.

Number of Shares

175,400

Previous 194,400 9.77%

Holding current value

$168,384

Previous $241,000 27.39%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.5 $17,480 - $28,500	-19,000 Reduced 9.77%	175,400 $175,000
Q2 2024 Aug 14, 2024	SELL	$0.73 - $1.38 $12,702 - $24,011	-17,400 Reduced 8.22%	194,400 $241,000
Q1 2024 May 15, 2024	SELL	$1.02 - $1.3 $2,958 - $3,770	-2,900 Reduced 1.35%	211,800 $275,000
Q4 2023 Feb 14, 2024	SELL	$0.75 - $1.49 $21,600 - $42,912	-28,800 Reduced 11.83%	214,700 $268,000
Q3 2023 Nov 14, 2023	SELL	$1.23 - $2.25 $112,422 - $205,650	-91,400 Reduced 27.29%	243,500 $316,000
Q2 2023 Aug 14, 2023	BUY	$1.24 - $1.92 $107,508 - $166,464	86,700 Added 34.93%	334,900 $576,000
Q1 2023 May 15, 2023	SELL	$1.34 - $2.62 $8,576 - $16,768	-6,400 Reduced 2.51%	248,200 $362,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $8,496 - $20,296	-5,900 Reduced 2.26%	254,600 $412,000
Q3 2022 Nov 14, 2022	BUY	$3.35 - $5.55 $208,370 - $345,210	62,200 Added 31.37%	260,500 $873,000
Q3 2022 Nov 14, 2022	BUY	$3.35 - $5.55 $208,370 - $345,210	62,200 Added 31.37%	260,500 $873,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $576,576 - $1.39 Million	184,800 Added 1368.89%	198,300 $722,000
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $47,576 - $109,592	-7,600 Reduced 36.02%	13,500 $98,000
Q4 2021 Feb 14, 2022	BUY	$11.35 - $21.18 $239,485 - $446,898	21,100 New	21,100 $287,000

Others Institutions Holding KRON

# of Institutions

Shares Held

19.8M

Call Options Held

9.3K

Put Options Held

100

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $54.5M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account